A case report on Transthyretin Cardiac Amyloidosis
G. Ziani *
Department of Cardiology B, Maternity Hospital Souissi, Mohammed V University, Rabat, Morocco.
H. Souilk
Department of Cardiology B, Maternity Hospital Souissi, Mohammed V University, Rabat, Morocco.
R. El Azouzi
Department of Cardiology B, Maternity Hospital Souissi, Mohammed V University, Rabat, Morocco.
A. Ameur
Department of Cardiology B, Maternity Hospital Souissi, Mohammed V University, Rabat, Morocco.
N. Doghmi
Department of Cardiology B, Maternity Hospital Souissi, Mohammed V University, Rabat, Morocco.
M. Cherti
Department of Cardiology B, Maternity Hospital Souissi, Mohammed V University, Rabat, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Introduction : Cardiac amyloidosis is due to the extracellular accumulation of insoluble fibrillar proteins which progressively alter the function of the myocardium. The prognosis depends on the severity of the cardiac involvement. Transthyretin cardiac amyloidosis (TTR) is the most common. It can be wild-type (ATTRwt), hereditary (ATTRv) or senile (wild TTR). The diagnosis of cardiac amyloidosis has greatly improved in the last decade and is based on multimodal imaging, mainly echocardiography and bone scintigraphy.
Case Report: We report the case of a male patient hospitalized for heart failure due to transthyretin cardiac amyloidosis.
Conclusion: Recognition of this pathology is essential because cardiological management is specific and conventional treatments for heart failure can be harmful. Only specific treatments can slow down or stop the infiltration process.
Keywords: Cardiac amyloidosis, diagnostic imaging, bone scintigraphy, TTR-stabilizing therapy